Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Search Results

Now showing 1 - 10 of 17

Some of the metrics are blocked by your
consent settings
Acute venous thromboembolism in patients with brain cancer: clinical course
(Elsevier BV, 2023-08)
Becattini, Cecilia
;
Giustozzi, Michela
;
Portillo, José
;
Fernández-Capitán, Carmen
;
Lobo, José Luis
Patients with brain cancer have been excluded or were underrepresented in studies on the treatment of venous thromboembolism (VTE), mainly due to the fear of intracranial hemorrhage (ICH).
Some of the metrics are blocked by your
consent settings
Identification of Low-risk Patients With Acute Symptomatic Pulmonary Embolism
(Elsevier BV, 2023-09)
Jiménez, David
;
Bikdeli, Behnood
;
Rodríguez, Carmen
;
Muriel, Alfonso
;
Ballaz, Aitor
Identification of patients with acute symptomatic pulmonary embolism (PE) who are at low-risk for short-term complications to warrant outpatient care lacks clarity.
Some of the metrics are blocked by your
consent settings
Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
(Wiley, 2021-01)
Camporese, Giuseppe
;
Simioni, Paolo
;
Di Micco, Pierpaolo
;
Fernández-Capitán, Carmen
;
Rivas, Agustina
Edoxaban is used for venous thromboembolism (VTE) treatment. Real-life data are lacking about its use in long-term therapy. We aimed to assess the efficacy and the safety of edoxaban for long-term VTE treatment in a real-life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis to identify predictors for the composite outcome was performed. From October 2015 to November 2019, 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, two patients developed recurrent VTE, six had major bleeding and nine died (2 from fatal bleeding). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio (HR) 8.37; 95% confidence interval (CI) 1.12-42.4) and a significant higher mortality rate (HR 31.1; 95% CI 4.63-262) than those receiving 60 mg. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no events, and a nonsignificantly higher mortality rate (HR 5.04; 95% CI 0.54-133) than those receiving 30 mg daily. In conclusion, edoxaban seems to be effective and safe for long-term VTE treatment in real life. Criteria for dose reduction should be reformulated.
Some of the metrics are blocked by your
consent settings
Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project
(SAGE Publications, 2020)
Tafur, Alfonso
;
Bikdeli, Behnood
;
Weinberg, Ido
;
Jimenez, David
;
Monreal, Annia
In the current era of patient empowerment and precision medicine, access to timely information is critical to decision-making. Unfortunately, we currently lack patient-specific, real-time data about clinical presentation, risk of thrombotic or hemorrhagic events, key risk factors, and adverse outcomes in patients with venous thromboembolism (VTE). Accordingly, the Registro Informatizado Enfermedad TromboEmbólica (RIETE) investigators developed a tool to provide an open-source, real-time graphic representation of VTE-related data derived from over 90 000 patients with confirmed VTE. This information is intended to facilitate discussion in the informed decision-making process. The current article describes the aims, rationale, methods, and ongoing and future efforts of the real-time VTE infographics developed by the RIETE registry collaborators.
Some of the metrics are blocked by your
consent settings
Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism
(Lippincott Williams & Wilkins, 2020-05)
Mehdipoor, Ghazaleh
;
Jimenez, David
;
Bertoletti, Laurent
;
Fidalgo, Ángeles
;
Sanchez Muñoz-Torrero, Juan Francisco
The choice of the imaging modality for diagnosis of pulmonary embolism (PE) could be influenced by provider, patient or hospital characteristics, or over time. However, little is known about the choice of the diagnostic modalities in practice. The aim of this study was to evaluate the variations in the use of imaging modalities for patients with acute PE.
Some of the metrics are blocked by your
consent settings
Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation
(Georg Thieme Verlag KG, 2020-07)
Quezada, Andrés
;
Jiménez, David
;
Bikdeli, Behnood
;
Muriel, Alfonso
;
Aramberri, Mario
The association between the use of inferior vena cava filters (IVCFs) and outcomes among patients with cancer-associated thromboembolism (CT) and contraindications to anticoagulation remains unclear.
Some of the metrics are blocked by your
consent settings
The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry
(Elsevier BV, 2023-04)
Prandoni, Paolo
;
Bilora, Franca
;
Mahé, Isabelle
;
Varona, José F
;
Pedrajas, José María
Some of the metrics are blocked by your
consent settings
Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study
(Elsevier BV, 2021-02)
Blondon, Marc
;
Jimenez, David
;
Robert-Ebadi, Helia
;
Del Toro, Jorge
;
Lopez-Jimenez, Luciano
Little is known about the prognosis of patients with massive pulmonary embolism (PE) and its risk of recurrent venous thromboembolism (VTE) compared with non-massive PE, which may inform clinical decisions. Our aim was to compare the risk of recurrent VTE, bleeding, and mortality after massive and non-massive PE during anticoagulation and after its discontinuation.
Some of the metrics are blocked by your
consent settings
Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score
(European Respiratory Society (ERS), 2020-07-23)
Jara-Palomares, Luis
;
Jiménez, David
;
Bikdeli, Behnood
;
Muriel, Alfonso
;
Rali, Parth
Improved prediction of the risk of major bleeding in patients with acute pulmonary embolism (PE) receiving systemic thrombolysis is crucial to guide the choice of therapy.
Some of the metrics are blocked by your
consent settings
Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi
(European Respiratory Society (ERS), 2020-11)
Bikdeli, Behnood
;
Jiménez, David
;
Muriel, Alfonso
;
Barrios, Deisy
;
Ballaz, Aitor

Faculty of Medicine

Browse

Filters

Settings

Sort By

Results per page

Search Results